PMC’s Amy Miller: Regulation, Reimbursement Policies Should Keep Up With Accelerated Pace of Scientific Advancement
WASHINGTON (Feb. 25, 2016)
The Personalized Medicine Coalition today commends the White House on the progress of the Precision Medicine Initiative (PMI) and encourages federal agencies to continue working toward regulation and reimbursement policies that align with its objectives.
"The downstream impact of the PMI will ultimately depend on the extent to which U.S. regulatory and reimbursement policies encourage the timely integration of personalized medicine into health care systems,” said Coalition Executive Vice President Amy M. Miller, Ph.D. "These policies should keep up with the accelerated pace of scientific advancement that the PMI cohort will facilitate.”
The Coalition is actively engaged with leaders at the U.S. Food and Drug Administration (FDA) and the Centers for Medicare and Medicaid Services (CMS) on the development of policies related to the regulatory environment for diagnostics and reimbursement for personalized medicine products and services. Miller said she is encouraged by the agencies' willingness to incorporate community perspectives into their work.
"We look forward to continuing our engagement with FDA and CMS as they evaluate the personalized medicine implications of their policies and with the leaders of the PMI to support their education and recruiting efforts for the cohort,” Miller said. "Carefully considered policies will help ensure that the PMI improves and extends the lives of many patients while concurrently transforming how all of us experience health care.”
Christopher J. Wells
About the Personalized Medicine Coalition:
The Personalized Medicine Coalition, representing innovators, scientists, patients, providers and payers, promotes the understanding and adoption of personalized medicine concepts, services and products to benefit patients and the health system. For more information about PMC, please visit www.personalizedmedicinecoalition.org.